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Abstract 
Autoimmune rheumatic diseases are characterised by systemic inflammation and complex 
immunopathology, with an increased risk of cardiovascular disease, initiated by endothelial 
dysfunction in a chronic inflammatory environment. Endothelial microparticles (EMPs) are 
released into the circulation from activated endothelial cells and may therefore, reflect 
disease severity, vascular and endothelial dysfunction, that could influence disease 
pathogenesis via autocrine/paracrine signalling. The exact function of EMPs in rheumatic 
disease remains unknown, and this has initiated research to elucidate EMP composition and 
function, which may be determined by the mode of endothelial activation and the micro 
environment. To date, EMPs are thought to play a role in angiogenesis, thrombosis and 
inflammation by transferring specific proteins and microRNAs (miRs) to target cells.  Here, 
we review the mechanisms underlying the generation and composition of EMPs and the 
clinical and experimental studies describing the involvement of EMPs in rheumatic diseases, 
since we have previously shown endothelial dysfunction and an elevated risk of 
cardiovascular disease are characteristics in systemic lupus erythematosus. We will also 
discuss the potential of EMPs as future biomarkers of cardiovascular risk in these diseases.   
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Abbreviations 
APC                                                                           Antigen Presenting Cells  
ANCA                                                                        Anti-Neutrophil Cytoplasmic Antibody 
AECA                                                                         Anti-Endothelial Cell Antibodies  
APL                                                                            Anti-phospholipid 
APS                                                                            Anti-phospholipid syndrome 
BVAS                                                                         Birmingham Vasculitis Activity Score  
CTD                                                                           Connective Tissue Disease 
DC                                                                             Dendritic Cell 
ECD                                                                           Endothelial Cell Dysfunction 
EMP                                                                          Endothelial microparticle 
eNOS                                                                       endothelial nitric oxide synthase 
EPC                                                                           Endothelial Progenitor Cell 
FMD                                                                         Flow Mediated Dilation 
FOI                                                                            Fluorescent Optical Imaging 
HC                                                                             Healthy Control 
HSP                                                                           Henoch-Schonlein Purpura 
ICAM                                                                        Intracellular Adhesion Molecule-1  
KD                                                                             Kawasaki Disease 
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LAC                                                                               Lupus Anticoagulant 
MV                                                                               MicroVesicle 
NO                                                                                Nitric Oxide 
PH                                                                                Pulmonary Hypertension 
PMP                                                                             Platelet Microparticle 
PMR                                                                             Polymyalgia Rheumatica 
PS                                                                                 Phosphatidylserine 
RA                                                                                Rheumatoid Arthritis 
SLE                                                                               Systemic Lupus Erythematosus 
SSc                                                                               Systemic Sclerosis 
TF                                                                                 Tissue Factor 
TNF-α                                                                          Tumour Necrosis Factor alpha 
 
 
 
 
 
 
 
5 
 
Need for new biomarkers in rheumatic disease 
Large epidemiology studies have demonstrated that cardiovascular events are a leading 
cause of morbidity and mortality in rheumatic diseases such as systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (RA) (1-3). This enhanced risk of premature 
atherosclerosis is independent of traditional risk factors and is partly attributable to 
persistent systemic inflammation, atherogenic therapies such as glucocorticoids, and a 
procoagulant environment (4).  Autoimmune rheumatic diseases such as SLE, RA and 
systemic sclerosis (SSc) have presented challenges in the clinic because of their unclear 
disease aetiology and their unpredictable disease progression, demanding a need for 
improved and more accurate assessment of disease activity, prognosis and co-morbidity, 
with a view to ultimately allow a more personalised approach to therapy. 
There are several reports linking elevated endothelial microparticles (EMPs) with the 
immunopathogenesis of rheumatic diseases, via their potential role in the regulation of 
inflammation, thrombosis and angiogenesis (5).  EMPs are of particular interest in SLE and 
related connective tissue diseases (CTDs), given the importance of the endothelium in both 
inflammatory disease manifestations and the role of endothelial dysfunction in the early 
stages of atherosclerosis. Endothelial cell dysfunction (ECD), characterised by a shift of the 
actions of the endothelium toward reduced vasodilation, a proinflammatory state and 
enhanced prothrombotic properties, is emerging as the common denominator for diverse 
and highly prevalent cardiovascular diseases. Mechanisms that participate in the reduced 
vasodilatory responses in endothelial dysfunction include reduced nitric oxide generation 
and oxidative excess. Upregulation of adhesion molecules, generation of chemokines such 
as macrophage chemoattractant peptide-1, and production of plasminogen activator 
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inhibitor-1 participate in the inflammatory response and contribute to a prothrombic state. 
Detachment and apoptosis of endothelial cells are associated phenomena (6).  
We and others, have associated elevated EMPs with cardiovascular diseases and a 
correlation with high atherosclerotic plaque grade (7-10). Furthermore, EMP composition 
may reflect as yet unidentified important biological functions in disease pathogenesis and 
vascular dysfunction, and contribute to the increased cardiovascular risk present in a 
number of inflammatory diseases. Our own studies have shown the number of circulating 
EMPs correlates with the inflammatory status of SLE, and inversely relates to endothelial 
function in this patient group, raising the interest in the potential use of EMPs as a 
biomarker for the increased cardiovascular risk in SLE (11).  
Characteristics of endothelial microparticles  
MPs, also referred to as microvesicles (MVs), may originate from different vascular cell 
types including platelets, monocytes, endothelial cells, red blood cells, and granulocytes. In 
health, it has been reported than >80% of circulating MPs express membrane antigens that 
suggest a platelet origin(12). MPs form when the asymmetrical distribution of lipids 
between the inner and outer leaflets of a plasma membrane is lost (13). Under resting 
conditions, phosphatidylserine (PS) is located almost exclusively in the inner monolayer (14). 
When cells undergo activation or apoptosis, PS translocation to the outer leaflet is the initial 
event that will ultimately lead to the shedding of MPs that are therefore regarded as 
markers of cell stress (13). The dynamic balance of cell stimulation, cell proliferation and 
death within the vessels is reflected by the formation and release of MPs that may thus 
represent a vascular storage pool of bioeffectors. 
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With regard to EMP release disruption of the endothelium occurs following activation or 
apoptotic cell death. This may be initiated and propagated by a variety of triggers (such as 
classic cardiovascular risk factors, inflammatory cytokines and complement activation), 
leading to conformational changes of the plasma membrane and the release of 
phosphatidylserine(PS)-exposing microparticles (15, 16).  EMPs are 100nm-1μm vesicular, 
anuclear structures comprising of proteins, micro-RNAs, mRNAs and enzymes specific to the 
cell from which they originate (17) , enabling paracrine and autocrine actions on cells of the 
vascular system (18).  
EMPs are elevated in numerous cardiovascular-related diseases with an impaired 
endothelial  component including coronary artery disease (7-9), carotid artery disease (10), 
stroke (19), familial hypercholesterolaemia (20), pulmonary hypertension (21), myocardial 
ischemia, preeclampsia, diabetes, metabolic syndrome as well as rheumatic diseases, 
suggesting that these microparticles represent a surrogate marker of ECD. To date it has 
been impossible to identify the specific vascular bed from which EMPs are derived due to a 
lack of specific surface markers; however, the total EMP population is thought to reflect the 
overall health of the endothelium. It should be noted that low levels of EMPs are also 
detected in healthy controls (10, 19, 21), suggesting that EMPs may also have a potential 
role in the homeostatic regulation of the healthy vascular endothelium. 
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Endothelial microparticle function   
It is increasingly recognised that EMP function is more nuanced than previously considered, 
and the micro-environment stimulating EMP release appears to be a key contributor to the 
functional properties exhibited by EMPs (22). In particular, the insult or injury that results in 
EMP release, namely cell apoptosis or activation, results in EMPs having distinctive and 
differing roles in disease, as highlighted by Jimenez et al (23). In order to interrogate the role 
played by EMPs in the context of inflammation, and endothelial dysfunction, EMP release 
and composition under inflammatory conditions and their subsequent effects have been 
studied using in vitro models. Much of this investigative work is performed on cells derived 
from large vascular beds such as Human Aortic Endothelial cells (HAoEC) and Human 
umbilical vein endothelial cells (HuVECs) (24, 25). 
Proteomic analysis of cell-culture derived EMPs has shown that one third of the proteins 
found on EMPs are specific to the stimulus initiating their release, not only demonstrating 
the plasticity of these vesicles but also revealing the complexity of the mechanisms 
governing their formation (26). Taken together, these findings suggest that there are distinct 
mechanisms for the formation of EMPs in apoptotic and activated cells (27), with several 
studies suggesting that these types of EMPs have different functions in vascular diseases 
(28, 29). Thus, we suggest EMPs may provide a measure of the health of the underlying 
endothelial. However, their utility as biomarkers of disease must also take into account 
potential differences between the healthy and disease states.  
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Pathogenic effects of endothelial microparticles on the endothelium   
A number of studies have shown that TNF-α, a key cytokine involved in the pathogenesis of 
a number of rheumatic diseases, activates endothelial cells and induces release of EMPs (24-
26). EMPs produced under these conditions have been used in a number of functional 
studies. High levels of the surface antigens E-selectin, intracellular adhesion molecule-1 
(ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) have been detected on EMPs 
derived from activated endothelial cells and can mediate adhesion of monocytes to 
endothelial cells in vitro (30). These data suggest that EMPs may be both a consequence and 
a cause of the inflammatory response. 
EMPs have also been shown to play a role in thrombosis (31). Phosphotidylserine (PS) is 
expressed on released EMPs, which confers a procoagulant property to EMPs, due to the 
ability of PS to bind and activate coagulation factors (32). It has been reported that EMPs 
also contain tissue factor (TF), which can initiate the extrinsic coagulation pathway (24, 33). 
This thrombogenic activity of EMPs has been confirmed by the demonstration that EMP-
triggered TF-dependent release, promotes thrombin formation in vitro and thrombus 
formation in vivo (34).  
EMPs impair vasorelaxation and bioavailability of endothelial-derived nitric oxide (NO) 
production by aortic cells in healthy animal models in a concentration-dependent manner, 
suggesting that circulating EMPs may directly affect endothelial-dependent vasodilatation 
and thus, not only act as a marker for ECD, but also potentially aggravate pre-existing ECD 
(35). 
EMPs isolated from end-stage renal disease patients with cardiovascular disease have been 
shown to impair the release of nitric oxide from vascular cells and platelet-derived MPs can 
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act as a source for thromboxane A2, which increases vascular contraction (36). EMPs may 
also be involved in cross-talk with the smooth muscle layer. Recent work has shown that 
EMPs produced under inflammatory conditions were able to induce vascular calcification in 
smooth muscle cells, thus contributing to vessel stiffness (37). 
Restorative effects of endothelial microparticles 
In contrast to their proposed role in ECD, we and others have detected a functional 
endothelial nitric oxide synthase (eNOS) in EMPs (38). In our in vitro study, EMPs were able 
to prevent lipid-induced endothelial dysfunction via Akt/eNOS signalling and attenuation of 
oxidative stress in ECs in vitro (Mahmoud et al 2015 under review) suggesting a protective 
role of EMPs in endothelial function. Indeed, Hussein et al demonstrated that EMP release 
could prevent apoptosis by diminishing levels of caspase-3 in cultured endothelial cells, by 
trapping caspase-3 within the released MPs (39). Thus, endothelial-derived MPs play a role 
in homeostasis and contribute to the sorting of several pro-apoptotic factors, preventing cell 
detachment and apoptosis.  
Furthermore, induction of endothelial repair mechanisms have been demonstrated using 
EMPs produced under different conditions. Tissue factor-containing EMPs produced under 
physical stress conditions, were able to promote neovascularisation by stimulating CCL20 via 
β1-integrin signalling, while high glucose-induced EMPs were able to transfer miR-126, 
promoting vascular repair via SPRED1 (40). The plasmin generation capacity of EMPs may be 
pivotal in maintaining vascular patency, since the proteolytic capacity of the plasminogen 
activation system has been shown to affect the angiogenic potential of endothelial 
progenitor cells in vitro, via extracellular matrix degradation and the release of growth 
factors (41). However, in contrast, cell culture-derived EMPs have also been shown to inhibit 
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angiogenesis in mouse models of atherosclerosis (42). In clinical studies, EMPs act in a 
vasculoprotective manner in conditions associated with acute vascular stresses, including 
septic shock (43). The various functions exhibited by EMPs are likely to reflect particular 
membrane and surface proteins specific to their parental cells and underpinned by a 
particular stimuli or environment thus, contributing to downstream regulatory mechanisms 
on target cells in a controlled and defined manner. Therefore, rather than being inert 
markers of injury, EMPs may act as downstream delivery systems for pro-inflammatory 
products that are vasculoprotective in acute inflammatory conditions, whilst also  having 
the capacity to, not only perpetuate further vascular dysfunction in chronic disease, but  
also act as surrogates of vascular dysfunction (11, 44-46) . How this translates to the effects 
observed in patients remains to be determined. 
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The role of endothelial microparticles in rheumatic diseases 
Rheumatoid arthritis 
It has been reported in a range of studies in RA patients that EMP (and total MP) numbers 
are increased in comparison to healthy controls (HC), as well as being associated with 
disease specific features such as disease activity (47). MPs isolated from RA patients 
demonstrate potent ability to activate the endothelium in vitro, whilst having a deleterious 
effect on endothelial cell function, thus supporting their role as a marker of vascular 
damage in disease (47). Similarly, our own group has previously reported that at a cellular 
level, a clinically available TNF-α inhibitor (Certolizumab) prevents TNF-α induced activation 
of the NF-κB pathway and prevents MP production by activated endothelial cells, suggesting 
a potential novel mechanism by which anti -TNF therapy may improve cardiovascular 
outcomes in inflammatory arthritis patients (25).  
Systemic Lupus Erythematosus 
EMPs have also been shown to be elevated in SLE, in both active and low disease activity 
states (11, 48). Anti-endothelial cell antibodies (AECAs) do not seem to be the main cause of 
endothelial dysfunction in this population, with EMPs instead being released from the 
endothelium of activated and apoptotic cells (48). In active SLE, EMP numbers are 
significantly related to objective measures of endothelial dysfunction, as assessed by flow 
mediated dilatation (FMD) (11). Similar to inflammatory arthritis, Parker et al demonstrated 
that improvement in disease control and suppression of inflammation was associated with 
improvement in both absolute EMP numbers and endothelial dysfunction in patients, 
suggesting that better control of active inflammatory disease may contribute to improved 
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cardiovascular risk in patients with SLE, further supporting the proposal that an EMP 
measure may be a useful surrogate marker (11). 
In addition to being associated with endothelial dysfunction, EMPs may contribute directly 
to the pathogenesis of disease, linking the endothelium to both disease aetiology and 
development of premature atherosclerosis. SLE patients exhibit a population of annexin 
V+/CD31+ /CD45- endothelial microparticles, not present in healthy subjects, RA or SSc 
patients, which contain apoptosis-modified chromatin. This microparticle subpopulation, 
when isolated from the plasma of SLE patients, increases the expression of co-stimulatory 
surface molecules and production of pro-inflammatory cytokines IL-6, TNF-α and IFN-α by 
blood-derived plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs), as 
well as priming blood-derived neutrophils for NETosis. These results underline the 
important role of apoptotic endothelial microparticles in driving the autoimmune response 
in SLE patients (49). This novel activation pathway may be implicated in various additional 
inflammatory disorders suggesting endothelial microparticles could be an important 
immunomodulatory therapeutic target (50). 
Sjogren’s Syndrome 
Similar to SLE, EMP numbers are elevated in Sjogren’s Syndrome and have been shown to 
be directly correlated with disease duration. Interestingly, early EPCs (CD34+CD309+CD133+) 
demonstrate an inverse correlation with disease duration, suggesting that the reparative 
potential of the endothelial layer is preserved in the earliest stages of disease, with 
progressive exhaustion of the precursor endothelial cell pool occurring as disease 
progresses,. In turn, this likely leads to a defective vascular layer restoration, manifesting as 
endothelial dysfunction (51). A similar mismatch in damage and repair mechanisms has 
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been observed in patients with Polymyalgia Rheumatica (PMR), where an increased 
EMP/EPC ratio has been noted, compared with controls, because of both increased EMP 
(CD31+/CD42-)  numbers and reduced EPC (CD34+/KDR+) levels. Notably improvement in 
disease activity following corticosteroid therapy leads to a parallel decline in the EMP/EPC 
ratio, adding strength to the proposal that an EMP/EPC ratio could act as a biomarker for 
response to treatment (52). 
Systemic Sclerosis 
Systemic Sclerosis (SSc) is characterised by microvascular involvement early in the disease 
course, potentially contributing, via tissue ischaemia, to the widespread fibrosis 
characteristic of this condition. Platelet-derived microparticles also make an important 
contribution to this disease upon activation, as their secretome contains a range of 
vasoactive mediators favouring vasoconstriction(e.g. thromboxane, serotonin) and growth 
factors (TGF-β,PDGF) that may contribute to fibrosis (53). The elevated levels of EMPs in SSc 
patients appear to correlate with organ involvement; eg.  Annexin V non-binding EMP 
concentrations correlate negatively with lung function parameters (DLco and FVC) in limited 
and diffuse cutaneous subsets of SSc (54). Similarly, the elevated EMP levels detected in 
pulmonary hypertension (PH), the leading cause of mortality in SSc patients, could reflect an 
increased vascular pro-coagulant and inflammatory state, which might be related to 
thrombo-embolic complications as well as PH progression (55).  Finally, EMPs also correlate 
with objective measures of vascular function/damage in SSc, as Jung et al have identified a 
strong association between EMPs and perivascular inflammation, quantified by 
Fluorescence Optical Imaging (FOI) in SSc and Raynaud’s patients and have suggested that 
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EMP measurement may be a potential biomarker of both diagnosis and response to therapy 
(56). 
Anti-Phospholipid Syndrome 
The antiphospholipid syndrome (APS) refers to persistent anti-phospholipid antibodies (aPL) 
associated with thrombotic and/or obstetrical complications. Because of their procoagulant 
and proinflammatory properties, EMPs have been implicated in the pathogenesis of 
antiphospholipid syndrome (APS). A number of studies have compared the levels of MPs in 
the blood of patients with primary APS, SLE patients with secondary APS, SLE patients with 
or without antiphospholipid antibodies (aPL) in the absence of secondary APS, and healthy 
individuals with or without aPL in the absence of thrombotic events. In general, these 
studies have reported elevated numbers of EMPs in patients with APS, lending credence to 
links of EMPs with thrombotic events and pregnancy complications (57-59). However, the 
precise contribution to thrombosis remains unclear. Interestingly, only APS plasma induced 
the release of EMP with procoagulant activity suggesting that generation of EMP in APS and 
SLE patients results from an autoimmune process involving aPL (60). 
In support of this, EMP levels were also associated with Lupus Anticoagulant (LA). In 
contrast however, Jy et al described elevated EMP counts in individuals with aPL, although 
this increase was independent of a history of thrombosis; PMP counts in contrast were 
increased only in patients with aPL and a thrombotic event (61). These findings suggest that 
aPL might cause chronic endothelial cell activation or injury, leading to the enhanced 
shedding of EMPs. Interestingly, aPL-positivity in SLE has also been associated with the 
presence of carotid plaque, supporting their role in chronic endothelial injury (62). In 
contrast, only certain aPL specificities might cause the activation of platelets and the release 
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of PMPs, which increase the risk for thrombosis. Therefore, the EMP/PMP ratio could be key 
to successful stratification within this patient group.  
Vasculitides  
Increased numbers of EMPs during the acute phase of vasculitides have also been reported, 
with patients in remission displaying normal levels (63). The numbers of EMPs correlate with 
the Birmingham Vasculitis Activity Score (BVAS) in children with different types of 
vasculitides and in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides in 
adults (64). Comparison of blood EMP levels with those of circulating endothelial cells, 
another potential biomarker for vasculitides, indicates that whilst both markers correlate 
with disease activity in ANCA-associated vasculitides, EMP levels decline faster after 
induction of remission (65). Similar findings have been demonstrated in paediatric vasculitis. 
In Kawasaki Disease (KD), when compared with healthy controls, there were significantly 
greater numbers of CD144+/CD42b-, CD62E+, and CD105+ EMPs in patients with negative 
correlations observed between the values of FMD and EMPs in the three phases of KD (66). 
Similar observations were made in Henoch-Schonlein Purpura (HSP) with EMP levels falling 
following treatment. Despite this reduction, patients in remission still exhibited higher EMP 
levels in comparison to healthy controls again suggesting their potential as a marker of 
subclinical inflammation in HSP (67). 
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Barriers to the use of endothelial microparticles as biomarkers.  
EMPs are identified and enumerated via flow cytometry using a panel of markers; most 
commonly Annexin V+ to indicate PS-positivity. Endothelial cell markers used vary between 
groups and the combination of CD31+/CD42b- is widely used (9, 68) but remains an 
imperfect choice (44, 64). Platelet cell adhesion molecule (PECAM-1 or CD31) is present on 
both endothelial and platelet-derived MPs (PMPs), therefore, CD42-negativity is used to 
exclude PMPs. Other combinations used to detect EMPs, include CD144 (VE-cadherin), CD54 
(intracellular adhesion molecule-1 (ICAM)), and CD62e (E-selectin) (44, 64). Again, these 
markers remain problematic as they only detect a sub-population of EMPs (for example, 
from activated endothelial cells only) and therefore may only be present at lower levels  (23, 
69) . The process of identifying and quantifying EMPs involves several distinct stages - blood 
collection, centrifugation, antibody detection of cell surface antigens, and flow cytometry – 
and there is significant variation at all stages, and there is a growing consensus that for 
accurate assessment of microparticles, a firm set of guidelines is needed (70, 71). Previous 
reviews have extensively highlighted the difficulties, methods and potential characteristic 
markers that may be used in this process (72). It may be that additional methods should be 
employed to enable accurate phenotyping, sizing, and enumeration of the wide range of 
MPs generated from different vascular beds and different cell types, in order to fully 
understand the biology of these microparticles. This may also remove variation between 
sample handling between different laboratories. These additional methods may include 
electron and atomic force microscopy, together with a full RNA, lipid, and protein profiling 
exercise.  
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Conclusion: Are endothelial microparticles friends or foes? 
In conclusion, EMPs can be considered as complex structures displaying a large repertoire of 
endothelial-derived molecules and biological functions, depending on their composition. 
When the data are taken together, the involvement of EMP in vascular homeostasis appears 
to be more complex than initially thought. EMPs can play a major role in inflammation, 
thrombosis, angiogenesis and repair as summarised in Figure 1. However, depending on the 
physiological or pathological context, the mechanisms and sites of formation, EMPs are 
emerging as having favourable effects to maintain vascular homeostasis. Further studies are 
warranted to establish whether these different EMP “phenotypes” and paradoxical effects 
are also found in vivo.  
The initial vision was that EMPs were noxious, supporting proinflammatory, procoagulant 
potential and inhibiting vascular repair. Increased levels of MPs of endothelial origin in 
various pathologies, such as atherothrombosis, vasculitis, and sepsis, also support this 
harmful potential. However, recent data have brought to light the beneficial effect of EMPs 
on endothelial integrity, such as stimulation of vascular repair, control of cell death 
mechanisms or cytoprotective activities supported by antigen presenting cells (APC), or 
induction of adaptive immunity. Therefore, we would do an injustice to the humble MP if 
we were to label them as either pathogenic or simple passive players in disease.  It is clear 
that MPs may play a role in homeostasis and could be protective, and because of their 
modulation in disease conditions, remain open to the possibility of acting as novel 
biomarkers of disease. 
 
 
19 
 
Competing financial Interests/Funding Statement 
None of the authors has received any financial support or other benefits from commercial 
sources for the work reported in this manuscript, nor do any of the authors have any other 
financial interests which could create a potential conflict of interest, or the appearance 
thereof. The views expressed in this publication are those of the author(s) and not 
necessarily those of the NHS, the National Institute for Health Research or the Department 
of Health.  
20 
 
References 
1. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and 
SLE. Nature reviews Rheumatology. 2011;7(7):399-408. 
2. Fernandez-Nebro A, Rua-Figueroa I, Lopez-Longo FJ, Galindo-Izquierdo M, Calvo-Alen J, 
Olive-Marques A, et al. Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study 
in Spain From the RELESSER Registry. Medicine. 2015;94(29):e1183. 
3. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, et al. Disease activity 
in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449-
55. 
4. Bruce IN. 'Not only...but also': factors that contribute to accelerated atherosclerosis and 
premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 
2005;44(12):1492-502. 
5. Distler JH, Pisetsky DS, Huber LC, Kalden JR, Gay S, Distler O. Microparticles as regulators of 
inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis and rheumatism. 
2005;52(11):3337-48. 
6. Endemann DH, Schiffrin EL. Endothelial dysfunction. Journal of the American Society of 
Nephrology : JASN. 2004;15(8):1983-92. 
7. Bernal-Mizrachi L, Jy W, Fierro C, Macdonough R, Velazques HA, Purow J, et al. Endothelial 
microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int J 
Cardiol. 2004;97(3):439-46. 
8. Werner N, Wassmann S, Ahlers P, Kosiol S, Nickenig G. Circulating CD31+/annexin V+ 
apoptotic microparticles correlate with coronary endothelial function in patients with coronary 
artery disease. Arterioscler Thromb Vasc Biol. 2006;26(1):112-6. 
9. Sinning JM, Losch J, Walenta K, Bohm M, Nickenig G, Werner N. Circulating CD31+/Annexin 
V+ microparticles correlate with cardiovascular outcomes. European heart journal. 
2011;32(16):2034-41. 
10. Schiro A, Wilkinson FL, Weston R, Smyth JV, Serracino-Inglott F, Alexander MY. Elevated 
levels of endothelial-derived microparticles, and serum CXCL9 and SCGF-beta are associated with 
unstable asymptomatic carotid plaques. Sci Rep. 2015;5:16658. 
11. Parker B, Al-Husain A, Pemberton P, Yates AP, Ho P, Gorodkin R, et al. Suppression of 
inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Annals of 
the rheumatic diseases. 2014;73(6):1144-50. 
12. Flaumenhaft R, Dilks JR, Richardson J, Alden E, Patel-Hett SR, Battinelli E, et al. 
Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived 
microparticles. Blood. 2009;113(5):1112-21. 
13. Freyssinet JM, Toti F. Formation of procoagulant microparticles and properties. Thrombosis 
research. 2010;125 Suppl 1:S46-8. 
14. Tesse A, Martinez MC, Meziani F, Hugel B, Panaro MA, Mitolo V, et al. Origin and biological 
significance of shed-membrane microparticles. Endocr Metab Immune Disord Drug Targets. 
2006;6(3):287-94. 
15. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in 
blood cells. Blood. 1997;89(4):1121-32. 
16. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of 
circulating microparticles. Arterioscler Thromb Vasc Biol. 2011;31(1):15-26. 
17. van der Pol E, Boing AN, Gool EL, Nieuwland R. Recent developments on the nomenclature, 
presence, isolation, detection and clinical impact of extracellular vesicles. J Thromb Haemost. 2015. 
18. Leroyer AS, Tedgui A, Boulanger CM. Role of microparticles in atherothrombosis. Journal of 
internal medicine. 2008;263(5):528-37. 
19. Simak J, Gelderman MP, Yu H, Wright V, Baird AE. Circulating endothelial microparticles in 
acute ischemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost. 
2006;4(6):1296-302. 
21 
 
20. Suades R, Padro T, Alonso R, Lopez-Miranda J, Mata P, Badimon L. Circulating CD45+/CD3+ 
lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial 
hypercholesterolaemia patients. Thrombosis and haemostasis. 2014;111(1):111-21. 
21. Amabile N, Heiss C, Real WM, Minasi P, McGlothlin D, Rame EJ, et al. Circulating endothelial 
microparticle levels predict hemodynamic severity of pulmonary hypertension. American journal of 
respiratory and critical care medicine. 2008;177(11):1268-75. 
22. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial 
dysfunction. Frontiers in bioscience : a journal and virtual library. 2004;9:1118-35. 
23. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release 
phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thrombosis 
research. 2003;109(4):175-80. 
24. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, et al. In vitro generation of 
endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. 
The Journal of clinical investigation. 1999;104(1):93-102. 
25. Heathfield SK, Parker B, Zeef LA, Bruce IN, Alexander MY. Certolizumab pegol attenuates the 
pro-inflammatory state in endothelial cells in a manner that is atheroprotective. Clinical and 
experimental rheumatology. 2013;31(2):225-33. 
26. Peterson DB, Sander T, Kaul S, Wakim BT, Halligan B, Twigger S, et al. Comparative 
proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles. Proteomics. 
2008;8(12):2430-46. 
27. Mackman N, Davis GE. Blood coagulation and blood vessel development: is tissue factor the 
missing link? Arterioscler Thromb Vasc Biol. 2011;31(11):2364-6. 
28. Yong PJ, Koh CH, Shim WS. Endothelial microparticles: missing link in endothelial 
dysfunction? Eur J Prev Cardiol. 2013;20(3):496-512. 
29. Rautou PE, Leroyer AS, Ramkhelawon B, Devue C, Duflaut D, Vion AC, et al. Microparticles 
from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion 
and transendothelial migration. Circulation research. 2011;108(3):335-43. 
30. Lee SK, Yang SH, Kwon I, Lee OH, Heo JH. Role of tumour necrosis factor receptor-1 and 
nuclear factor-kappaB in production of TNF-alpha-induced pro-inflammatory microparticles in 
endothelial cells. Thrombosis and haemostasis. 2014;112(3):580-8. 
31. Mooberry MJ, Key NS. Microparticle analysis in disorders of hemostasis and thrombosis. 
Cytometry A. 2015. 
32. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. Interaction of 
endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent 
procoagulant activity. Blood. 2002;99(11):3962-70. 
33. Arderiu G, Pena E, Badimon L. Angiogenic microvascular endothelial cells release 
microparticles rich in tissue factor that promotes postischemic collateral vessel formation. 
Arterioscler Thromb Vasc Biol. 2015;35(2):348-57. 
34. Abid Hussein MN, Boing AN, Biro E, Hoek FJ, Vogel GM, Meuleman DG, et al. Phospholipid 
composition of in vitro endothelial microparticles and their in vivo thrombogenic properties. 
Thrombosis research. 2008;121(6):865-71. 
35. Brodsky SV, Zhang F, Nasjletti A, Goligorsky MS. Endothelium-derived microparticles impair 
endothelial function in vitro. Am J Physiol Heart Circ Physiol. 2004;286(5):H1910-5. 
36. Pfister SL. Role of platelet microparticles in the production of thromboxane by rabbit 
pulmonary artery. Hypertension. 2004;43(2):428-33. 
37. Buendia P, Montes de Oca A, Madueno JA, Merino A, Martin-Malo A, Aljama P, et al. 
Endothelial microparticles mediate inflammation-induced vascular calcification. FASEB J. 
2015;29(1):173-81. 
38. Horn P, Cortese-Krott MM, Amabile N, Hundsdorfer C, Kroncke KD, Kelm M, et al. Circulating 
microparticles carry a functional endothelial nitric oxide synthase that is decreased in patients with 
endothelial dysfunction. J Am Heart Assoc. 2013;2(1):e003764. 
22 
 
39. Abid Hussein MN, Boing AN, Sturk A, Hau CM, Nieuwland R. Inhibition of microparticle 
release triggers endothelial cell apoptosis and detachment. Thrombosis and haemostasis. 
2007;98(5):1096-107. 
40. Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, Proebsting S, et al. Endothelial 
microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via 
SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation. 
2013;128(18):2026-38. 
41. Lacroix R, Sabatier F, Mialhe A, Basire A, Pannell R, Borghi H, et al. Activation of plasminogen 
into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic 
properties of endothelial progenitor cells in vitro. Blood. 2007;110(7):2432-9. 
42. Ou ZJ, Chang FJ, Luo D, Liao XL, Wang ZP, Zhang X, et al. Endothelium-derived microparticles 
inhibit angiogenesis in the heart and enhance the inhibitory effects of hypercholesterolemia on 
angiogenesis. Am J Physiol Endocrinol Metab. 2011;300(4):E661-8. 
43. Mostefai HA, Meziani F, Mastronardi ML, Agouni A, Heymes C, Sargentini C, et al. Circulating 
microparticles from patients with septic shock exert protective role in vascular function. American 
journal of respiratory and critical care medicine. 2008;178(11):1148-55. 
44. Amabile N, Guerin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, et al. Circulating 
endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal 
failure. Journal of the American Society of Nephrology : JASN. 2005;16(11):3381-8. 
45. Bulut D, Maier K, Bulut-Streich N, Borgel J, Hanefeld C, Mugge A. Circulating endothelial 
microparticles correlate inversely with endothelial function in patients with ischemic left ventricular 
dysfunction. J Card Fail. 2008;14(4):336-40. 
46. Esposito K, Ciotola M, Schisano B, Gualdiero R, Sardelli L, Misso L, et al. Endothelial 
microparticles correlate with endothelial dysfunction in obese women. J Clin Endocrinol Metab. 
2006;91(9):3676-9. 
47. Rodriguez-Carrio J, Alperi-Lopez M, Lopez P, Alonso-Castro S, Carro-Esteban SR, Ballina-
Garcia FJ, et al. Altered profile of circulating microparticles in rheumatoid arthritis patients. Clin Sci 
(Lond). 2015;128(7):437-48. 
48. Duval A, Helley D, Capron L, Youinou P, Renaudineau Y, Dubucquoi S, et al. Endothelial 
dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and 
characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies. 
Rheumatology (Oxford). 2010;49(6):1049-55. 
49. Dieker J, Tel J, Pieterse E, Thielen A, Rother N, Bakker M, et al. Circulating apoptotic 
microparticles in SLE patients drive the activation of DC subsets and prime neutrophils for NETosis. 
Arthritis Rheumatol. 2015. 
50. Angelot F, Seilles E, Biichle S, Berda Y, Gaugler B, Plumas J, et al. Endothelial cell-derived 
microparticles induce plasmacytoid dendritic cell maturation: potential implications in inflammatory 
diseases. Haematologica. 2009;94(11):1502-12. 
51. Bartoloni E, Alunno A, Bistoni O, Caterbi S, Luccioli F, Santoboni G, et al. Characterization of 
circulating endothelial microparticles and endothelial progenitor cells in primary Sjogren's 
syndrome: new markers of chronic endothelial damage? Rheumatology (Oxford). 2015;54(3):536-44. 
52. Pirro M, Bocci EB, Di Filippo F, Schillaci G, Mannarino MR, Bagaglia F, et al. Imbalance 
between endothelial injury and repair in patients with polymyalgia rheumatica: improvement with 
corticosteroid treatment. Journal of internal medicine. 2012;272(2):177-84. 
53. Pauling JD, O'Donnell VB, McHugh NJ. The contribution of platelets to the pathogenesis of 
Raynaud's phenomenon and systemic sclerosis. Platelets. 2013;24(7):503-15. 
54. Iversen LV, Ullman S, Ostergaard O, Nielsen CT, Halberg P, Karlsmark T, et al. Cross-sectional 
study of soluble selectins, fractions of circulating microparticles and their relationship to lung and 
skin involvement in systemic sclerosis. BMC Musculoskelet Disord. 2015;16:191. 
23 
 
55. Diehl P, Aleker M, Helbing T, Sossong V, Germann M, Sorichter S, et al. Increased platelet, 
leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in 
pulmonary hypertension. J Thromb Thrombolysis. 2011;31(2):173-9. 
56. Jung C, Drummer K, Oelzner P, Figulla HR, Boettcher J, Franz M, et al. The association 
between endothelial microparticles and inflammation in patients with systemic sclerosis and 
Raynaud's phenomenon as detected by functional imaging. Clin Hemorheol Microcirc. 2015. 
57. Breen KA, Sanchez K, Kirkman N, Seed PT, Parmar K, Moore GW, et al. Endothelial and 
platelet microparticles in patients with antiphospholipid antibodies. Thrombosis research. 
2015;135(2):368-74. 
58. Chaturvedi S, Cockrell E, Espinola R, Hsi L, Fulton S, Khan M, et al. Circulating microparticles 
in patients with antiphospholipid antibodies: characterization and associations. Thrombosis 
research. 2015;135(1):102-8. 
59. Patil R, Ghosh K, Satoskar P, Shetty S. Elevated procoagulant endothelial and tissue factor 
expressing microparticles in women with recurrent pregnancy loss. PloS one. 2013;8(11):e81407. 
60. Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, et al. Endothelial 
microparticles: a potential contribution to the thrombotic complications of the antiphospholipid 
syndrome. Thrombosis and haemostasis. 2004;91(4):667-73. 
61. Jy W, Tiede M, Bidot CJ, Horstman LL, Jimenez JJ, Chirinos J, et al. Platelet activation rather 
than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid 
antibodies. Thrombosis research. 2007;121(3):319-25. 
62. Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, et al. Subclinical 
atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors 
and the lupus phenotype. Rheumatology (Oxford). 2007;46(6):983-8. 
63. Kumpers P, Erdbrugger U, Grossheim M, Meyer GP, Hiss M, Gwinner W, et al. Endothelial 
microparticles as a diagnostic aid in Churg-Strauss vasculitis-induced cardiomyopathy. Clinical and 
experimental rheumatology. 2008;26(3 Suppl 49):S86-9. 
64. Brogan PA, Shah V, Brachet C, Harnden A, Mant D, Klein N, et al. Endothelial and platelet 
microparticles in vasculitis of the young. Arthritis and rheumatism. 2004;50(3):927-36. 
65. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, Woywodt A, et al. Diagnostic role of 
endothelial microparticles in vasculitis. Rheumatology (Oxford). 2008;47(12):1820-5. 
66. Guiducci S, Ricci L, Romano E, Ceccarelli C, Distler JH, Miniati I, et al. Microparticles and 
Kawasaki disease: a marker of vascular damage? Clinical and experimental rheumatology. 2011;29(1 
Suppl 64):S121-5. 
67. Dursun I, Dusunsel R, Poyrazoglu HM, Gunduz Z, Patiroglu T, Ulger H, et al. Circulating 
endothelial microparticles in children with Henoch-Schonlein purpura; preliminary results. 
Rheumatology international. 2011;31(12):1595-600. 
68. Preston RA, Jy W, Jimenez JJ, Mauro LM, Horstman LL, Valle M, et al. Effects of severe 
hypertension on endothelial and platelet microparticles. Hypertension. 2003;41(2):211-7. 
69. Huber J, Vales A, Mitulovic G, Blumer M, Schmid R, Witztum JL, et al. Oxidized membrane 
vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce 
monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol. 2002;22(1):101-7. 
70. Shet AS. Characterizing blood microparticles: technical aspects and challenges. Vascular 
health and risk management. 2008;4(4):769-74. 
71. Dey-Hazra E, Hertel B, Kirsch T, Woywodt A, Lovric S, Haller H, et al. Detection of circulating 
microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. 
Vascular health and risk management. 2010;6:1125-33. 
72. Xu R, Greening DW, Zhu HJ, Takahashi N, Simpson RJ. Extracellular vesicle isolation and 
characterization: toward clinical application. The Journal of clinical investigation. 2016;126(4):1152-
62. 
 
24 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1. An illustration to highlight the multiple roles that EMPs may play in the pathogenesis of 
autoimmune rheumatic diseases and the potential signalling pathways involved in repair of the vessel 
wall. PMPs; platelet microparticles, EMPs; endothelial microparticles, CAC; circulating angiogenic cells, 
eNOS; endothelial nitric oxide synthase, SMCs; smooth muscle cells.     
